Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 1,819 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the transaction, the insider now owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Blueprint Medicines Price Performance
NASDAQ:BPMC opened at $95.39 on Tuesday. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of -45.21 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The business has a 50 day simple moving average of $92.15 and a 200-day simple moving average of $97.39. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. During the same period in the previous year, the firm earned ($2.20) earnings per share. Blueprint Medicines's quarterly revenue was up 126.5% compared to the same quarter last year. Equities analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current year.
Hedge Funds Weigh In On Blueprint Medicines
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings | Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
Hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC purchased a new position in shares of Blueprint Medicines during the second quarter valued at approximately $1,060,000. Federated Hermes Inc. lifted its stake in shares of Blueprint Medicines by 27.8% during the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company's stock worth $6,721,000 after acquiring an additional 13,579 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company's stock worth $23,332,000 after acquiring an additional 82,693 shares during the last quarter. Nicholas Investment Partners LP bought a new position in Blueprint Medicines in the 2nd quarter valued at $4,377,000. Finally, Entropy Technologies LP purchased a new stake in Blueprint Medicines in the third quarter worth $999,000.
Analysts Set New Price Targets
Several research analysts recently weighed in on the stock. Guggenheim reaffirmed a "buy" rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Thursday, November 14th. JMP Securities restated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Monday, December 9th. Finally, StockNews.com raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $122.11.
View Our Latest Stock Report on BPMC
Blueprint Medicines Company Profile
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
